Sino Biopharmaceutical Limited has announced that its innovative drug, TQC3721 inhalation suspension, a PDE3/4 inhibitor, has received approval from the Center for Drug Evaluation $(CDE)$ of the National Medical Products Administration of China to commence a phase III registrational clinical study. This study aims to explore the maintenance treatment for chronic obstructive pulmonary disease (COPD). TQC3721, known for its bronchodilatory and anti-inflammatory effects, is noted for its advanced research and development progress, ranking second worldwide. This phase III trial will include patients with dual bronchodilators as part of their background treatment, broadening its scope to cover a wider range of COPD patients. Additionally, an inhaled dry powder formulation of TQC3721 is in phase I clinical development, expected to enhance patient compliance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.